“Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II”, J of Skin, vol. 8, no. 2, p. s396, Mar. 2024, doi: 10.25251/skin.8.supp.396.